Apnimed, Inc. (NASDAQ:APMD – Get Free Report)’s stock price reached a new 52-week low on Monday. The company traded as low as $16.12 and last traded at $16.37, with a volume of 130,191 shares traded. The stock had previously closed at $16.40.
Analyst Ratings Changes
Several analysts have recently issued reports on APMD shares. Weiss Ratings assumed coverage on Apnimed in a report on Tuesday, October 27th. They set a “sell (e-)” rating on the stock. Lifesci Capital began coverage on Apnimed in a research note on Tuesday, August 25th. They set an “outperform” rating and a $50.00 target price for the company. Evercore assumed coverage on shares of Apnimed in a report on Tuesday, August 25th. They set an “outperform” rating on the stock. Zacks Research raised shares of Apnimed to a “hold” rating in a research report on Wednesday, August 26th. Finally, Cantor Fitzgerald initiated coverage on shares of Apnimed in a research note on Tuesday, August 25th. They issued an “overweight” rating and a $60.00 price target on the stock. Four research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Apnimed has an average rating of “Moderate Buy” and an average price target of $50.33.
View Our Latest Stock Report on Apnimed
Apnimed Trading Down 5.1%
The stock has a market cap of $647.76 million and a PE ratio of 5.92. The stock’s 50 day moving average is $22.93.
Apnimed (NASDAQ:APMD – Get Free Report) last released its quarterly earnings data on Tuesday, September 8th. The company reported $0.51 earnings per share for the quarter. The business had revenue of $12.08 million during the quarter. As a group, research analysts forecast that Apnimed, Inc. will post -0.24 earnings per share for the current year.
Apnimed Company Profile
Apnimed Inc is a clinical-stage pharmaceutical company focused on developing medicines for sleep-related breathing disorders, particularly obstructive sleep apnea (OSA). The company is developing oral therapies intended to address the underlying physiological causes of OSA rather than relying solely on mechanical devices such as continuous positive airway pressure machines.
Apnimed’s lead program is AD109, an investigational once-daily oral therapy designed to improve upper-airway muscle activity during sleep.
Featured Articles
- Five stocks we like better than Apnimed
- GLP-1 Focus or Broader Peptide Exposure: Which ETF Has the Edge?
- Mortgage Rates Froze U.S. Housing, But These 3 Overseas Markets Still Pay Double Digits
- Big Tech Is Spending Billions on AI—These 5 Stocks Are Getting Paid
- 3 Waste Services Stocks With More Growth Than You Might Expect
Receive News & Ratings for Apnimed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apnimed and related companies with MarketBeat.com's FREE daily email newsletter.
-logo-1200x675.png){kind=logo}
